{
    "root": "42cbc3f1-41ac-4b3e-9cd0-65c9caa8caf8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Synjardy",
    "value": "20250324",
    "ingredients": [
        {
            "name": "EMPAGLIFLOZIN",
            "code": "HDC1R2M35U"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        }
    ],
    "indications": "synjardy synjardy combination empagliflozin , sodium-glucose co-transporter 2 ( sglt2 ) inhibitor metformin hydrochloride ( hcl ) immediate-release , biguanide , indicated adjunct diet exercise improve glycemic control adults pediatric patients aged 10 years older type 2 diabetes mellitus . synjardy xr synjardy xr combination empagliflozin , sglt2 inhibitor metformin hcl extended-release , biguanide , indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . empagliflozin empagliflozin , used component synjardy synjardy xr , indicated adults type 2 diabetes mellitus reduce risk : cardiovascular ( cv ) death adults established cv disease . ( 1 ) cv death hospitalization heart failure adults heart failure . ( 1 ) sustained decline egfr , end-stage kidney disease , cv death , hospitalization adults chronic kidney disease risk progression . ( 1 ) limitations : recommended improve glycemic control patients type 1 diabetes mellitus . may increase risk diabetic ketoacidosis patients . ( 1 ) metformin hcl component , synjardy synjardy xr limited patients type 2 diabetes mellitus . ( 1 ) empagliflozin , used component synjardy synjardy xr , recommended treatment chronic kidney disease patients polycystic kidney disease patients requiring recent history intravenous immunosuppressive therapy greater 45 mg prednisone equivalent kidney disease . empagliflozin expected effective . ( 1 )",
    "contraindications": "assess renal function initiating clinically indicated . assess volume status correct volume depletion initiating . ( 2.1 ) individualize starting based patient 's current regimen renal function . ( 2.2 , 2.3 , 2.4 ) maximum recommended 25 mg/day empagliflozin 2,000 mg/day metformin hcl . ( 2.2 , 2.3 ) initiation synjardy synjardy xr recommended patients egfr less 45 ml/min/1.73 2 , due metformin hcl component . ( 2.4 ) synjardy : take orally twice daily meals , gradual escalation reduce gastrointestinal due metformin hcl . ( 2.2 , 2.3 ) synjardy xr : take orally daily meal morning , gradual escalation reduce gastrointestinal due metformin hcl . swallow whole ; split , crush , dissolve , chew . ( 2.2 ) synjardy synjardy xr may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.5 ) withhold synjardy synjardy xr least 3 days , possible , prior surgery procedures associated prolonged fasting . ( 2.6 )",
    "warningsAndPrecautions": "synjardy tablets available follows : tablet strength color/shape tablet markings package size ndc number 5 mg empagliflozin500 mg metformin hcl orange yellow , oval , biconvex , film-coated tablet boehringer ingelheim company symbol `` s5 `` debossed one side ; side debossed `` 500 `` . bottles 60bottles 180 0597-0159-600597-0159-18 5 mg empagliflozin 1,000 mg metformin hcl brownish yellow , oval , biconvex , film-coated tablet boehringer ingelheim company symbol `` s5 `` debossed one side ; side debossed `` 1000 `` . bottles 60bottles 180 0597-0175-600597-0175-18 12.5 mg empagliflozin 500 mg metformin hcl pale brownish purple , oval , biconvex , film-coated tablet boehringer ingelheim company symbol `` s12 `` debossed one side ; side debossed `` 500 `` . bottles 60bottles 180 0597-0180-600597-0180-18 12.5 mg empagliflozin 1,000 mg metformin hcl dark brownish purple , oval , biconvex , film-coated tablet boehringer ingelheim company symbol `` s12 `` debossed one side ; side debossed `` 1000 `` . bottles 60bottles 180 0597-0168-600597-0168-18 synjardy xr extended-release tablets available follows : tablet strength color/shape tablet markings package size ndc number 5 mg empagliflozin1,000 mg metformin hcl olive green , oval , biconvex , film-coated tablet printed one side black ink boehringer ingelheim company symbol `` s5 `` top line `` 1000 `` bottom line . bottles 60bottles 180 0597-0290-740597-0290-59 10 mg empagliflozin1,000 mg metformin hcl orange , oval , biconvex , film-coated tablet printed one side black ink boehringer ingelheim company symbol `` s10 `` top line `` 1000 `` bottom line . bottles 30bottles 90 0597-0280-730597-0280-90 12.5 mg empagliflozin 1,000 mg metformin hcl blue , oval , biconvex , film-coated tablet printed one side black ink boehringer ingelheim company symbol `` s12 `` top line `` 1000 `` bottom line . bottles 60bottles 180 0597-0300-450597-0300-93 25 mg empagliflozin 1,000 mg metformin hcl light green , oval , biconvex , film-coated tablet printed one side black ink boehringer ingelheim company symbol `` s25 `` top line `` 1000 `` bottom line . bottles 30bottles 90 0597-0295-880597-0295-78",
    "adverseReactions": "synjardy synjardy xr contraindicated patients : severe renal impairment ( egfr less 30 ml/min/1.73 m2 ) [ ( 5.1 ) ( 8.6 ) ] . acute chronic metabolic acidosis , including diabetic ketoacidosis [ ( 5.1 ) ] . hypersensitivity empagliflozin , metformin hcl excipients synjardy synjardy xr , angioedema occurred [ ( 5.9 ) ] .",
    "indications_original": "SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 )",
    "contraindications_original": "Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) Individualize the starting dosage based on the patient's current regimen and renal function. ( 2.2 , 2.3 , 2.4 ) The maximum recommended dosage is 25 mg/day of empagliflozin and 2,000 mg/day of metformin HCl. ( 2.2 , 2.3 ) Initiation of SYNJARDY or SYNJARDY XR is not recommended in patients with an eGFR less than 45 mL/min/1.73 m 2 , due to the metformin HCl component. ( 2.4 ) SYNJARDY: take orally twice daily with meals, with gradual dosage escalation to reduce the gastrointestinal adverse reactions due to metformin HCl. ( 2.2 , 2.3 ) SYNJARDY XR: take orally once daily with a meal in the morning, with gradual dosage escalation to reduce the gastrointestinal adverse reactions due to metformin HCl. Swallow whole; do not split, crush, dissolve, or chew. ( 2.2 ) SYNJARDY or SYNJARDY XR may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.5 ) Withhold SYNJARDY or SYNJARDY XR at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. ( 2.6 )",
    "warningsAndPrecautions_original": "SYNJARDY tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           Tablet Strength\n                           Color/Shape\n                           Tablet Markings\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           5 mg Empagliflozin500 mg Metformin HCl\n                           orange yellow, oval, biconvex, film-coated tablet\n                           Boehringer Ingelheim company symbol and \"S5\" debossed on one side; the other side is debossed with \"500\".\n                           Bottles of 60Bottles of 180\n                           0597-0159-600597-0159-18\n                        \n                        \n                           5 mg Empagliflozin 1,000 mg Metformin HCl\n                           brownish yellow, oval, biconvex, film-coated tablet\n                           Boehringer Ingelheim company symbol and \"S5\" debossed on one side; the other side is debossed with \"1000\".\n                           Bottles of 60Bottles of 180\n                           0597-0175-600597-0175-18\n                        \n                        \n                           12.5 mg Empagliflozin 500 mg Metformin HCl\n                           pale brownish purple, oval, biconvex, film-coated tablet\n                           Boehringer Ingelheim company symbol and \"S12\" debossed on one side; the other side is debossed with \"500\".\n                           Bottles of 60Bottles of 180\n                           0597-0180-600597-0180-18\n                        \n                        \n                           12.5 mg Empagliflozin 1,000 mg Metformin HCl\n                           dark brownish purple, oval, biconvex, film-coated tablet\n                           Boehringer Ingelheim company symbol and \"S12\" debossed on one side; the other side is debossed with \"1000\".\n                           Bottles of 60Bottles of 180\n                           0597-0168-600597-0168-18\n                        \n                     \n                  \n                  SYNJARDY XR extended-release tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           Tablet Strength\n                           Color/Shape\n                           Tablet Markings\n                           Package Size\n                           NDC Number\n                        \n                     \n                     \n                        \n                           5 mg Empagliflozin1,000 mg Metformin HCl\n                           olive green, oval, biconvex, film-coated tablet\n                           Printed on one side in black ink with the Boehringer Ingelheim company symbol and \"S5\" on the top line and \"1000 M\" on the bottom line.\n                           Bottles of 60Bottles of 180\n                           0597-0290-740597-0290-59\n                        \n                        \n                           10 mg Empagliflozin1,000 mg Metformin HCl\n                           orange, oval, biconvex, film-coated tablet\n                           Printed on one side in black ink with the Boehringer Ingelheim company symbol and \"S10\" on the top line and \"1000 M\" on the bottom line.\n                           Bottles of 30Bottles of 90\n                           0597-0280-730597-0280-90\n                        \n                        \n                           12.5 mg Empagliflozin 1,000 mg Metformin HCl\n                           blue, oval, biconvex, film-coated tablet\n                           Printed on one side in black ink with the Boehringer Ingelheim company symbol and \"S12\" on the top line and \"1000 M\" on the bottom line.\n                           Bottles of 60Bottles of 180\n                           0597-0300-450597-0300-93\n                        \n                        \n                           25 mg Empagliflozin 1,000 mg Metformin HCl\n                           light green, oval, biconvex, film-coated tablet\n                           Printed on one side in black ink with the Boehringer Ingelheim company symbol and \"S25\" on the top line and \"1000 M\" on the bottom line.\n                           Bottles of 30Bottles of 90\n                           0597-0295-880597-0295-78",
    "adverseReactions_original": "SYNJARDY and SYNJARDY XR are contraindicated in patients with:\n                  \n                     severe renal impairment (eGFR less than 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].\n                     \n                     acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.1)].\n                     \n                     hypersensitivity to empagliflozin, metformin HCl or any of the excipients in SYNJARDY or SYNJARDY XR, reactions such as angioedema have occurred [see Warnings and Precautions (5.9)]."
}